Abstract | INTRODUCTION: Administering pegfilgrastim on the same day as chemotherapy can improve patient satisfaction through convenience and may increase the utilization of cost-effective biosimilars compared to next-day administration, but the effect on clinical outcomes with commonly used breast cancer regimens is unclear. METHODS: RESULTS: A total of 360 patients were reviewed (146 same-day administration and 214 next-day administration). In the same-day group 36 patients (24.6%) developed FN compared to 25 patients (11.7%) in the next-day group (p = 0.002). Same-day administration also significantly increased the incidences of additional acute care visits (11.6% vs 2.8%, p = 0.0016), grade ≥ 3 neutropenia (38.4% vs 13.6%, p < 0.0001), chemotherapy dose reductions (21.2% vs 6.1%, p < 0.0001), and antibiotic use (26.7% vs 12.6%, p = 0.001). Same-day administration did not significantly increase the rate of hospitalization (15% vs 11.2%, p = 0.36) and delay of next chemotherapy cycle by ≥1 day (8.2% vs 6.1%, p = 0.57) due to neutropenic complications. CONCLUSIONS:
|
Authors | Jacob Hobbs, Jan Lowe, Abigale Ferdinand, Anna Shook, Bradley Beck, Danielle Blais, Cole Borchardt, Bing Xu |
Journal | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
(J Oncol Pharm Pract)
Vol. 29
Issue 8
Pg. 1853-1861
(Dec 2023)
ISSN: 1477-092X [Electronic] England |
PMID | 36579812
(Publication Type: Journal Article)
|
Chemical References |
- pegfilgrastim
- Granulocyte Colony-Stimulating Factor
- N,N-dimethyl-N-hexadecyl-1-octadecylammonium
- Biosimilar Pharmaceuticals
- Filgrastim
- Polyethylene Glycols
- Doxorubicin
- Cyclophosphamide
- Recombinant Proteins
|
Topics |
- Humans
- Adolescent
- Female
- Breast Neoplasms
(drug therapy, complications)
- Retrospective Studies
- Granulocyte Colony-Stimulating Factor
- Chemotherapy-Induced Febrile Neutropenia
(epidemiology, prevention & control, drug therapy)
- Biosimilar Pharmaceuticals
(therapeutic use)
- Filgrastim
(therapeutic use)
- Polyethylene Glycols
- Doxorubicin
(adverse effects)
- Cyclophosphamide
- Antineoplastic Combined Chemotherapy Protocols
- Recombinant Proteins
(therapeutic use)
|